Skip to main content

Advertisement

Table 4 Patients with grade 3 or 4 anaemia, leucopenia or thrombocytopenia by demographic, treatment and clinical variables. Number (per cent).

From: Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO

Variable Category n Grade 3/4 leucopenia p Grade 3/4 anaemia p Grade 3/4 thrombocytopenia p
B symptoms No 311 124 (39.9) < 0.001 14 (4.5) 0.011 17 (5.5) < 0.001
  Yes 353 203 (57.5)   34 (9.6)   48 (13.6)  
Sex Female 311 159 (51.1) 0.363 25 (8.0) 0.450 33 (10.6) 0.504
  Male 353 168 (47.6)   23 (6.5)   32 (9.1)  
Age < 75 years 496 226 (45.6) 0.001 33 (6.7) 0.324 40 (8.1) 0.010
  ≥ 75 years 168 101 (60.1)   15 (8.9)   25 (14.9)  
Chemotherapy CHOP 334 129 (38.6) < 0.001 27 (8.1) 0.392 40 (12.0) 0.056
  PMitCEBO 330 198 (60.0)   21 (6.4)   25 (7.6)  
GCSF No 330 184 (55.8) < 0.001 14 (4.2) 0.003 25 (7.6) 0.056
  Yes 334 143 (42.8)   34 (10.2)   40 (12.0)  
Stage Stage 0–2 246 99 (40.2) < 0.001 14 (5.7) 0.240 11 (4.5) < 0.001
  Stage 3–4 418 228 (54.5)   34 (8.1)   54 (12.9)  
Performance status Level 0–1 470 197 (41.9) < 0.001 27 (5.7) 0.012 25 (5.3) < 0.001
  Level 2–4 183 125 (68.3)   21 (11.5)   39 (21.3)  
LDH (mU/L) Normal 216 96 (44.4) 0.038 7 (3.2) 0.008 5 (2.3) < 0.001
  Elevated 381 203 (53.3)   34 (8.9)   52 (13.6)  
Bone marrow aspirate Negative 508 248 (48.8) 0.005 31 (6.1) 0.046* 45 (8.9) 0.004
  Positive 57 39 (68.4)   8 (14.0)   12 (21.1)  
Bone marrow Negative 487 228 (46.8) 0.001 30 (6.2) 0.083 40 (8.2) 0.001
Trephine Positive 89 58 (65.2   10 (11.2)   18 (20.2)  
  1. * Fisher exact p